As on 24th August 2020, a commercial-stage biopharmaceutical company announced that its amisulpride (selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist) injection has been launched and is now available in the US for order and distribution to customers via main wholesalers and speciality distributors. 

On 26 February 2020, this injection was FDA-approved for the management of postoperative nausea & vomiting (PONV). PONV is a frequent complication of surgery. It is linked with the usage of anesthetic gases and opioid analgesics, which is especially common following abdominal, gynecological, eye, and ear surgeries, especially those with a duration of an hour or more. This injection is the only antiemetic agent which has been approved as a rescue PONV treatment in patients who have unsuccessful earlier antiemetic prophylaxis of other drug class. 

This injection is expected to be in high demand as US healthcare organizations pursue to address surgical buildups created by the coronavirus crisis, mentioned the company’s CEO.